Last checked at 23 Nov 2015 07:00
23 November 2015
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Two new US platform programme accounts opened
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added two further new accounts to its platform programme in the USA.
The first new account is a major teaching hospital in the mid-west region of the USA and is the second platform programme account in the Great Lakes sales territory which the Company established in the first quarter of 2015.
The hospital has indicated that it intends to purchase at least 40 probes per month during its initial implementation phase, which the Company expects to increase as the technology is more widely adopted. Approximately 20 probes per month are scheduled to be used in the hospital's breast reconstruction surgical protocols to be launched in January 2016.
The second new account is a large hospital in Washington State. It is the fourth platform programme account in the North-West sales territory, and the fourth platform programme account from the 26 strong hospital system with which the Company implemented a system-wide procurement framework agreement in January 2015. The agreement requires each hospital that participates to commit to purchase at least 30 adult surgical probes a month. The three existing accounts are all on track to get to 100 or more probes per month: they are each now regularly purchasing 50 to 65 probes per month having started their implementation programmes at 30 to 35 probes a month. This fourth new account's first order was for 50 probes.
The new account contains a full service children's hospital with a large regional catchment area. Following a successful evaluation of the Company's newly launched paediatric probes, the Company has entered discussions with the hospital system to expand the purchasing agreement to include paediatric probes.
These are the third and fourth new platform programme accounts that Deltex has secured in the last three months bringing the total number of US platform accounts to 15, including nine new ones in the year to date, further illustrating the success of the Company's ongoing strategy to focus on the USA and develop it as our key market.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"The USA continues to be an increasingly important market for us and we see it moving towards becoming our key territory for development as adoption rates continue to outperform our other areas of focus. We look forward to working with the teams at both these new accounts and are pleased to have the eighth and ninth accounts added to our US platform programme this year and the fourteenth and fifteenth in total. Deltex Medical is now half way towards our current goal of 30 US hospitals on our platform programme by mid-2016."
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman |
|
Ewan Phillips, Chief Executive |
|
Jonathan Shaw, Finance Director Barry Curtis, Company Secretary |
|
|
|
Nominated Adviser & Broker |
|
Arden Partners plc | 020 7614 5900 |
Chris Hardie
|
|
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson
|
020 3829 5000
|
Financial Public Relations |
|
IFC Advisory | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
|
|
|
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.